are largely complete, and our efforts are focused on continuing to deploy the ABM playbook. At CFT, we continue to roll out the ATS business model focused on opportunities to further synergies in our supply chains and cost structures, and completed several ABM activities. These included standard work events, a raw material problem-solving event, and a communication Kaizen, which drove increased awareness and engagement across the business. AT ATs, our innovation activities are ongoing as they form part of our expand strategy. In the past quarter, we have completed a number of projects and initiatives that have resulted in the launch of a new high-speed debug camera, GMP testing, and certification of our super track pharma product, and the development of a new energy management software program that will enable customers to track and reduce their carbon footprint. We're pleased that our acquired company are also innovators. At the recent Chicago Process Ex- Expo, our NCC business won the Innovation Award for the sanitary design of the NCC side drive conveyance system. We have filed a patent for this system, which has multiple applications, including raw and packaged food products. Congratulations to the whole NCC team, well done. In summary, the results of the quarter and year to date demonstrate the strength and resiliency of our business and portfolio offerings. Record order booking activity reflects the alignment we have with our customers in providing best-in class solutions. Going forward, we are unwavering in our commitment to protecting and engaging our employees, serving our customers well and creating value for our shareholders. We will execute on these priorities through the application of the ABM playbook, with a goal… produced through the application of the ABM playbook with the goal of driving continuous improvement in our performance. Our record order backlog provides good revenue visibility, while the healthy balance sheet enables pursuit of organic growth and strategic M&A opportunities. Our objective is to build a great ATS business and we're making progress every day towards our collective goal. Now, I'll turn the call over to Ryan. Ryan, over to you. Thank you, Andrew. And good morning, ladies and gentlemen this morning, I will provide an overview of our Q3 operating results that featured growth and revenues both year over year in and sequentially, adjusted EBIT margin expansion and record order bookings and backlog. I will then review our balance sheet, which we have deployed strategically to expand our customer capabilities and earnings potential. Starting with operating results, bookings were $671 million up 54% compared to Q3 last year. Organic growth in bookings was 18%, partially offset by a 5% headwind from foreign exchange translation. Organic growth came from transportation as a result of new and follow on work in EV, energy markets due to follow on work and consumer products due to a large customer program, one during the quarter. Acquisitions contributed 41% growth in order bookings with the majority coming in food and beverage due to several new programs booked by our CFT businesses. An a trailing 12 month basis, our book to bill ratio was 1.15 to one, positioning us well for continued organic revenue growth. Moving to revenues, our Q3 top line increased 48% over Q3 last year. Organic growth was 22% due to higher order backlog entering the quarter, as well as year over year growth in service and parts revenues. Foreign exchange was a 5% headwind compared to Q3 last year. Acquired companies added 31% to revenue growth with CFT and SP the primary contributors. Due to seasonality and as expected, CFT revenues were lower in comparison to Q2, going forward, CFT is well positioned with a healthy order backlog following a very strong order bookings result in Q3. Our Q3 ending backlog of 1.5 billion was 50% higher than Q3 last year. Looking forward, our revenue conversion for Q4 is estimated to be in the 35 to 40% range of order backlog. As a reminder, this estimate is based on revenue expectations for both the exit execution of projects from backlog and work that will be booked and billed within the quarter. Moving to margins, Q3 gross margin included 5.1 million of cost related to the fair value adjustment of inventories acquired through acquisition activity. Excluding this adjustment, Q's adjusted gross margin was 29.8%, 200 basis points higher than the comparable period a year ago. Higher gross margin reflected operating efficiencies from strong project execution, improvements in the cost structure of our core business through previous reorganizations, increased service revenues and other continuous improvement efforts achieved by deploying our ABF. Disruptions and supply chain have led to increase lead times and in some cases, increases in cost in our supply base. To date, this has not had a material impact on our profitability. Our teams have implemented countermeasures, including advancing order timing and securing alternative sources of supply to mitigate inflationary pressures and lengthening lead times. Even with these countermeasures, supply chain pressures remain dynamic and will continue to present a challenge to or mitigation efforts going forward. Moving to SG&A, expenses were 43.6 million higher than Q3 last year. This year's costs included 16.7 million of acquisition related amortization and 6.3 million of acquisition related transaction costs. Excluding these items in both periods, Q'3 threes SG&A was 79.9 million, 25.9 million higher than last year. Reflecting incremental SG&A costs from acquired companies, primarily CFT, BioDot, and SP. Third quarter stock compensation expense was 12.7 million up from 4.9 million last year. Q3 adjusted earnings from operations were 70.4 million or 12.9% compared to 43.8 million or 11.8% last year. The increase in margin reflected efficiency gains made in our cost structure through effectively implemented reorganizations, improved program execution and increased after sale service revenues compared to a year ago. Excluding acquisitions, our core business operated with a 14.3% adjusted earnings from operations margin, up 250 basis points of our Q3 last year. Adjusted earnings margins from our acquired businesses were 7.4%. As expected, we saw a sequential reduction in earnings BioDot, as business volumes normalized following a period of higher demand for COVID related products. As expected, CFT operated at a low single digit even margin in the third quarter, actions to improve the cost structure of the business and drive savings through supply chain synergies are underway and on track. In the quarter, supply chain savings were partially offset by increased cost of materials, such as stainless steel. We are confident that the ongoing deployment of the ABM at CFT, including core tools such as daily visual management, problem solving and Kaiser events will drive improvements in the business. As previously announced, we also took action to reorganize certain CFT subsidiaries, including closing two facilities and consolidating product lines. These actions will drive cost efficiencies in line with our plan and bring focus to areas with a stronger value proposition. Restruction costs of 4.2 million were incurred in the third quarter. Integration of SP and DF are in the early stages. Our teams are working to achieve identified synergies between our pharma businesses, including ATS Life Sciences, Coma Chair, and now with the addition to SP and DF. Q3 adjusted EPS was 52 cents